Targets › NDUFS1
1 program from 1 company in 1 trial: 1 Phase 4; Metabolic and endocrine; next expected readout Mar 2027.
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor. Essential for catalysing the entry and efficient transfer of electrons within complex I. Plays a key role in the assembly and stability of complex I and participates in the association of complex I with…. (UniProt, P28331)
Open in Phaseline: the race on NDUFS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Center for Global Health and Medicine, Japan | Imeglimin Mitochondrial complex I modulator | NDUFS1 | Phase 4 | Diabetes Mellitus, Type 2 | Mar 2027 |
Diabetes Mellitus, Type 2 (1)
small molecule (1)
National Center for Global Health and Medicine, Japan (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.